hopper drug deal questions remain?

I wasn't able to attend today's meeting and so don't know whether chairman Wayne Millen was asked - or answered - these questions:

1. Who/what has Paul Hopper's Pathway Oncology acquired the GGTI-2418 license from?

2. What are the consideration terms?

3. Why did former license holder - Florida-based Tigris Pharmaceuticals, now Kirax Corporation - terminate the Stage 1 trial of the platform in 2009 - some three years after license rights were first acquired.

The trial was conducted by eminent Dr Peter O'Dwyer, a professor at the University of Pennsylvania's School of Medicine.

One scientific researcher says he believes the drug to be "dead and buried".

While I don't necessarily accept this conclusion, I suggest the performance background and outlook for the aging technology is problematic.

As confirmed at today's meeting, further trials of the drug are to be conducted by Moffitt Cancer Center, Florida and Monterfiore Einstein Center for Cancer Care, New York.

Another question remains: How will Virax fund further trialling of GGTI-2418?

Meanwhile, outcome of today's voting may be that Paul Hopper controls up to 30% of Virax capital.

Paul Hopper seems set to vault over Dr Wayne hopper as Virax's key man.